EUROPE Archives

Artificial Intelligence (AI) is transforming the fight against cancer.The European Cancer Organisation’s “Harnessing AI for Cancer Care in Europe” report

Artificial Intelligence (AI) is transforming the fight against cancer, enabling machines to learn, reason, and assist humans in detecting, diagnosing and treating the disease more accurately and efficiently. It works by analysing vast amounts of data, learning patterns, and making predictions or recommendations to support human decision-making.

Cancer care is rapidly transforming with the use of AI, which serves as a powerful tool in prevention, detection, treatment and research of the disease. The European Cancer Organisation’s “Harnessing AI for Cancer Care in Europe” report states that AI has the potential to transform every stage of the cancer pathway. Simultaneously, the report emphasises the need for AI to be used responsibly, by protecting patients, upholding ethical standards, and aligning with European values, to ensure its benefits are delivered fairly and effectively across healthcare systems.

The Promise of AI in Cancer Care

The report highlights several ways AI can improve cancer outcomes across the care pathway. In primary prevention, AI can analyse genetic, environmental, and lifestyle data to identify high-risk patients and guide preventive strategies before symptoms appear. For early detection, AI can dramatically speed up screening, reducing test interpretation from days to hours, improving accuracy, and lowering missed diagnoses. In diagnostics, deep-learning models trained on large datasets can detect even the smallest lesions, prioritise urgent cases, and support more precise diagnoses. AI also enables personalised treatment by integrating tumour genomics, imaging data, and real-world outcomes to help clinicians select the most effective therapies for individual patients. Finally, in drug development, AI can identify promising compounds and targets, shortening traditional development cycles and discovering new uses for existing medicines.

Challenges That Cannot Be Ignored

However, the report also highlights significant risks associated with AI in cancer care. Key concerns include regulatory gaps as AI tools advance faster than current rules, making it challenging to ensure they remain safe, accurate, and accountable. Many promising AI systems require further validation in real-world clinical settings, as untested tools could lead to misdiagnoses or unsafe decisions. Bias and inequity are also risks, since AI trained on unrepresentative data may produce less accurate recommendations for specific patient groups. Implementation barriers, such as limited infrastructure, funding, and trained staff, can hinder the integration of AI into everyday healthcare. Finally, trust issues may arise, as both patients and clinicians need to understand and have confidence in AI systems for them to be effectively adopted.

Policy Recommendations: A Roadmap for Safe and Effective Use

To tackle these challenges, the report puts forward four key recommendations. First, it calls for national standards and validation frameworks, including speciality-specific rules and post-market monitoring of AI tools. Second, it emphasises the importance of training and literacy, proposing pan-European AI education to ensure that at least 50% of oncology professionals are confident in using AI by 2030. Third, the report urges robust regulatory guidance and oversight, including EU-wide support for data protection under GDPR, implementation of the AI Act, and strong patient engagement to ensure clinical accountability. Finally, it highlights the need for investment in data infrastructure, leveraging the European Health Data Space to harmonise systems, modernise cancer registries, and build representative datasets that support safe and effective AI deployment.

Why This Matters for Kapa3

Building on these advancements, K3 is preparing to launch its digital assistant, “Myrto”, in 2026. Designed to harness the power of AI, “Myrto” will support patients and healthcare professionals across the cancer care pathway. By integrating cutting-edge AI capabilities with user-friendly guidance, “Myrto” exemplifies K3’s commitment to improving outcomes, streamlining workflows, and empowering both patients and clinicians in Europe’s rapidly evolving healthcare landscape.

To see the full article, please click here.

https://www.europeancancer.org/resources/publications/harnessing-ai-for-cancer-care-in-europe.html

KAPA3 at the ESMO Congress: Inspiration and Confirmation That We Are Moving Towards the Future

From October 17 to 20, we attended the ESMO World Congress in Berlin. The event stood out for the active participation of the Greek medical community, which led presentations on clinical data, Real-World Evidence, and up-to-date education in collaboration with the global oncology community. At the same time, Greek teams received awards in various areas (medical, nursing, institutional), inspiring us all with hope for the ongoing developments in oncology care.

Our main goal as KAPA3 was to focus on research addressing the real needs of the population within the framework of the global community. Collaborating with healthcare professionals from around the world allowed us to gather valuable knowledge and experiences. The intensive sessions and discussions broadened our understanding and prompted reflection on the next steps.

Key challenges identified for the patient advocacy community were:

Mandatory multidisciplinary assessment before starting treatment
No patient should begin treatment without undergoing a multidisciplinary assessment, including an oncology nurse, social scientist, and psychologist. This should be considered the minimum standard for all cancer patients.
Certification and quality of multidisciplinary teams
It is our duty to ensure that these teams meet quality standards. Their certification is undoubtedly complex. However, for us at KAPA3, multidisciplinary care is a fundamental criterion for service provision and must be certified. Quality care can significantly improve patient outcomes, as shown by clinical studies and research presented at this year’s congress, with potential improvements in overall survival of up to 10% (Sweden).

We are deeply proud that our work is guided by these standards precisely. In an era of remarkable progress in medicine and new therapies, we continue to strengthen the institution of research and multidisciplinary care, ensuring accessibility and patient-centered approaches aimed at quality of life.

This is the third time we have presented our efforts at an ESMO congress, in collaboration with the International University and the Nursing Department, highlighting our presence at every level. Meanwhile, trainings for other healthcare professionals take place annually within our organization in collaboration with Greek universities.

For Greek patients and their environment, we have not yet reached a point where the quality of care is considered a key objective for the entire oncology community. Our aim is to align with efforts across Europe so that, in the future, multidisciplinary assessments from the first day of diagnosis become standard practice within therapeutic protocols.

At KAPA3, we understand that quality care, inherently multidisciplinary, requires collective effort and collaboration between organizations and professionals to determine the best possible standards.

Digital poverty and social exclusion

Internet of Things in EU Households: Who is Connecting and How

A recent Eurostat article looks at how individuals across the European Union are using internet-connected devices (IoT).

In 2024, 70% of EU citizens aged 16–74 reported using Internet of Things (IoT) devices—smart technologies such as internet-connected TVs, smart speakers, fitness trackers, or doorbells. While internet-connected TVs were the most widely used device (58%), wearables like smartwatches or fitness trackers were used by 30%, and home audio systems by 19%. Less common were smart home appliances, energy management systems, security devices, health-related IoT devices, and toys.

Usage patterns vary across age groups. The youngest adults (16–24) show the highest adoption of entertainment-related IoT devices, while the 35–44 age group uses more home-related devices.

Country differences are significant: the Netherlands leads with 95% of citizens using IoT devices, while Greece ranks fourth from the last, just above Romania, Bulgaria, and Poland.

The trend towards digital inequality is concerning. Special attention is needed from social justice actors to avoid automation-driven discrimination facilitated by artificial intelligence. While digitalisation can enhance the efficiency of social protection, there is a risk it may instead serve austerity measures.